130 related articles for article (PubMed ID: 8271954)
41. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Baker MS; Liang XM; Doe WF
Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
[TBL] [Abstract][Full Text] [Related]
42. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
43. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
44. Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi).
Behrendt N; Danø K
FEBS Lett; 1997 Feb; 402(2-3):293-4. PubMed ID: 9037213
[No Abstract] [Full Text] [Related]
45. Urokinase receptors in human monocytes.
Nykjaer A; Petersen CM; Christensen EI; Davidsen O; Gliemann J
Biochim Biophys Acta; 1990 May; 1052(3):399-407. PubMed ID: 2162216
[TBL] [Abstract][Full Text] [Related]
46. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
47. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
Schlechte W; Murano G; Boyd D
Cancer Res; 1989 Nov; 49(21):6064-9. PubMed ID: 2551498
[TBL] [Abstract][Full Text] [Related]
48. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.
Ploug M; Kjalke M; Rønne E; Weidle U; Høyer-Hansen G; Danø K
J Biol Chem; 1993 Aug; 268(23):17539-46. PubMed ID: 8394346
[TBL] [Abstract][Full Text] [Related]
49. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
50. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
51. Interaction of urokinase A chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator.
Fibbi G; Magnelli L; Pucci M; Del Rosso M
Exp Cell Res; 1990 Mar; 187(1):33-8. PubMed ID: 2153567
[TBL] [Abstract][Full Text] [Related]
52. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
53. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
54. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
55. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo.
Sidenius N; Sier CF; Blasi F
FEBS Lett; 2000 Jun; 475(1):52-6. PubMed ID: 10854857
[TBL] [Abstract][Full Text] [Related]
56. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
57. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator.
Nolli ML; Corti A; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787
[TBL] [Abstract][Full Text] [Related]
58. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
60. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line.
Hollas W; Soravia E; Mazar A; Henkin J; Blasi F; Boyd D
Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):629-34. PubMed ID: 1322138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
